Yokoyama Takahiro, Hamasuna Ryoichi, Ohta Hajime, Takeshima Hideo
Department of Neurosurgery, Saito-Koyu Medical Center, Saito, Miyazaki, Japan.
Department of Neurosurgery, Division of Clinical Neuroscience, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki, Japan.
J Neuroendovasc Ther. 2020;14(2):48-55. doi: 10.5797/jnet.oa.2019-0060. Epub 2020 Jan 10.
To retrospectively analyze the complication rates and risk factors associated with the use of the Angio-Seal vascular closure device during neuroendovascular therapy.
In this study, we enrolled 283 patients who underwent Angio-Seal hemostasis between December 2005 and June 2019 at our institute. We retrospectively analyzed the major and minor complication rates and risk factors between the complication and no-complication groups using the medical charts of patients for whom the device was used.
Of the 283 patients, 5 had major complications (1.8%) and 18 had minor complications (6.3%). There were no significant differences between the complication (n = 23) and no-complication (n = 260) groups regarding the baseline characteristics or operation procedures. Among the major complications, superficial femoral artery puncture, 8Fr device, Angio-Seal Evolution, post-carotid artery stenting, dual antiplatelet therapy, and delirium were considered risk factors.
The Angio-Seal is a safe and useful hemostatic device. However, puncture site complications need to be considered when the device is used for contraindicated patients or for those with delirium who cannot rest following the procedure.
回顾性分析血管内神经治疗期间使用Angio-Seal血管闭合装置的并发症发生率及相关危险因素。
本研究纳入了2005年12月至2019年6月在我院接受Angio-Seal止血治疗的283例患者。我们使用该装置使用者的病历,回顾性分析了并发症组和无并发症组的主要和次要并发症发生率及危险因素。
283例患者中,5例发生主要并发症(1.8%),18例发生次要并发症(6.3%)。并发症组(n = 23)和无并发症组(n = 260)在基线特征或手术操作方面无显著差异。在主要并发症中,股浅动脉穿刺、8Fr装置、Angio-Seal Evolution、颈动脉支架置入术后、双重抗血小板治疗和谵妄被认为是危险因素。
Angio-Seal是一种安全有效的止血装置。然而,当该装置用于禁忌患者或术后无法安静休息的谵妄患者时,需要考虑穿刺部位并发症。